A Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of ABBV-181 (Budigalimab) in Adult Participants With Human Immunodeficiency Virus (HIV)-1

NCT04223804 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

41

Enrollment

INDUSTRY

Sponsor class

Conditions

Human Immunodeficiency Virus (HIV)
HIV Infection
HIV-1

Interventions

DRUG: ABBV-181
DRUG: Placebo

Sponsor

AbbVie